<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398732</url>
  </required_header>
  <id_info>
    <org_study_id>B1801412</org_study_id>
    <nct_id>NCT04398732</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients</brief_title>
  <official_title>Efficacy of Etanercept in Iraqi Patients With Moderate to Severe Psoriasis: 5 Years Data From Local Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      This study is to evaluate available local data in Iraqi patients with moderate to severe
      psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and
      patient characterization (i.e. age, gender, smoking status) using data from the
      Dermatologists in Baghdad Teaching Hospital registry
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from base line in the body surface area (BSA) score for patients with moderate to severe plaque psoriasis treated with etanercept</measure>
    <time_frame>January 1, 2014 through Jan 1, 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe plaque psoriasis by the change of BSA from baseline to the end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from base line in the Dermatology Life Quality Index (DLQI) score for patients with moderate to severe plaque psoriasis treated with etanercept</measure>
    <time_frame>January 1, 2014 through Jan 1, 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe plaque psoriasis by the change of DLQI from baseline to the end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from base line in the Psoriasis Area and Severity Index (PASI) score for patients with moderate to severe plaque psoriasis treated with etanercept</measure>
    <time_frame>January 1, 2014 through Jan 1, 2019</time_frame>
    <description>The assessment of efficacy of etanercept in patients with moderate to severe plaque psoriasis by the change of PASI from baseline to the end of the study.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Patients with moderate to severe plaque psoriasis</arm_group_label>
    <description>Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enbrel</intervention_name>
    <description>As provided in real world practice</description>
    <arm_group_label>Patients with moderate to severe plaque psoriasis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients data from the local registry at the Dermatology Center of Baghdad Teaching
        Hospital registry.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept
             treatment for a minimum duration of 1 year.

          -  Age â‰¥18 years old.

          -  No history of using a biological treatment, other than etanercept, for treatment of
             moderate to severe plaque psoriasis or any other reason.

        Exclusion Criteria:

          -  Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year
             duration.

          -  Previous use of other biological treatments for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer</name>
      <address>
        <city>Baghdad</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

